A novel obatoclax derivative, SC-2001, induces apoptosis in hepatocellular carcinoma cells through SHP-1-dependent STAT3 inactivation

Cancer Letters

Volumn 321, Issue 1, 2012, Pages 27-35

  Chen, Kuen Feng ^b   Su, Jung Chen ^a   Liu, Chun Yu ^a,d   Huang, Jui Wen ^e   Chen, Kuei Chiu ^b   Chen, Wei Lin ^a   Tai, Wei Tien ^b,c   Shiau, Chung Wai ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^e INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE   (Taiwan)

Author keywords

HCC; Obatoclax; SC 2001; SHP 1; STAT3

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN D1; INTERLEUKIN 6; OBATOCLAX; PROTEIN BAK; PROTEIN BCL XL; PROTEIN MCL 1; PROTEIN TYROSINE PHOSPHATASE SHP 1; SC 2001; STAT3 PROTEIN; SURVIVIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL STRAIN HEPG2; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; TRANSCRIPTION TERMINATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; HUMANS; LIVER NEOPLASMS; MICE; MICE, NUDE; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 6; PYRROLES; STAT3 TRANSCRIPTION FACTOR;

EID: 84860331447     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.03.023     Document Type: Article

References (45)

1. C. Verslype, E. Van Cutsem, M. Dicato, N. Arber, J.D. Berlin, D. Cunningham, A. De Gramont, E. Diaz-Rubio, M. Ducreux, T. Gruenberger, D. Haller, K. Haustermans, P. Hoff, D. Kerr, R. Labianca, M. Moore, B. Nordlinger, A. Ohtsu, P. Rougier, W. Scheithauer, H.J. Schmoll, A. Sobrero, J. Tabernero, C. van de Velde, The management of hepatocellular carcinoma. In: Current Expert Opinion and Recommendations Derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008, Ann. Oncol. 20 (Suppl. 7) (2009) vii1-vii6.
2. Tanaka S., Arii S. Molecularly targeted therapy for hepatocellular carcinoma. Cancer Sci. 2009, 100:1-8.
3. Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.F., de Oliveira A.C., Santoro A., Raoul J.L., Forner A., Schwartz M., Porta C., Zeuzem S., Bolondi L., Greten T.F., Galle P.R., Seitz J.F., Borbath I., Haussinger D., Giannaris T., Shan M., Moscovici M., Voliotis D., Bruix J. Sorafenib in advanced hepatocellular carcinoma. New Engl. J. Med. 2008, 359:378-390.
4. Cheng A.L., Kang Y.K., Chen Z., Tsao C.J., Qin S., Kim J.S., Luo R., Feng J., Ye S., Yang T.S., Xu J., Sun Y., Liang H., Liu J., Wang J., Tak W.Y., Pan H., Burock K., Zou J., Voliotis D., Guan Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009, 10:25-34.
5. Mott J.L., Gores G.J. Piercing the armor of hepatobiliary cancer: Bcl-2 homology domain 3 (BH3) mimetics and cell death. Hepatology 2007, 46:906-911.
6. Marzo I., Naval J. Bcl-2 family members as molecular targets in cancer therapy. Biochem. Pharmacol. 2008, 76:939-946.
7. Fleischer B., Schulze-Bergkamen H., Schuchmann M., Weber A., Biesterfeld S., Muller M., Krammer P.H., Galle P.R. Mcl-1 is an anti-apoptotic factor for human hepatocellular carcinoma. Int. J. Oncol. 2006, 28:25-32.
8. Sieghart W., Losert D., Strommer S., Cejka D., Schmid K., Rasoul-Rockenschaub S., Bodingbauer M., Crevenna R., Monia B.P., Peck-Radosavljevic M., Wacheck V. Mcl-1 overexpression in hepatocellular carcinoma: a potential target for antisense therapy. J. Hepatol. 2006, 44:151-157.
9. Takehara T., Liu X., Fujimoto J., Friedman S.L., Takahashi H. Expression and role of Bcl-xL in human hepatocellular carcinomas. Hepatology 2001, 34:55-61.
10. Watanabe J., Kushihata F., Honda K., Mominoki K., Matsuda S., Kobayashi N. Bcl-xL overexpression in human hepatocellular carcinoma. Int. J. Oncol. 2002, 21:515-519.
11. Huang Z. Bcl-2 family proteins as targets for anticancer drug design. Oncogene 2000, 19:6627-6631.
12. Hwang J.J., Kuruvilla J., Mendelson D., Pishvaian M.J., Deeken J.F., Siu L.L., Berger M.S., Viallet J., Marshall J.L. Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma. Clin. Cancer Res. 2010, 16:4038-4045.
13. O'Brien S.M., Claxton D.F., Crump M., Faderl S., Kipps T., Keating M.J., Viallet J., Cheson B.D. Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood 2009, 113:299-305.
14. Paik P.K., Rudin C.M., Brown A., Rizvi N.A., Takebe N., Travis W., James L., Ginsberg M.S., Juergens R., Markus S., Tyson L., Subzwari S., Kris M.G., Krug L.M. A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies. Cancer Chemother. Pharm. 2010, 66:1079-1085.
15. Schimmer A.D., O'Brien S., Kantarjian H., Brandwein J., Cheson B.D., Minden M.D., Yee K., Ravandi F., Giles F., Schuh A., Gupta V., Andreeff M., Koller C., Chang H., Kamel-Reid S., Berger M., Viallet J., Borthakur G. A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies. Clin. Cancer Res. 2008, 14:8295-8301.
16. Germain D., Frank D.A. Targeting the cytoplasmic and nuclear functions of signal transducers and activators of transcription 3 for cancer therapy. Clin. Cancer Res. 2007, 13:5665-5669.
17. Li W.C., Ye S.L., Sun R.X., Liu Y.K., Tang Z.Y., Kim Y., Karras J.G., Zhang H. Inhibition of growth and metastasis of human hepatocellular carcinoma by antisense oligonucleotide targeting signal transducer and activator of transcription 3. Clin. Cancer Res. 2006, 12:7140-7148.
18. Kusaba M., Nakao K., Goto T., Nishimura D., Kawashimo H., Shibata H., Motoyoshi Y., Taura N., Ichikawa T., Hamasaki K., Eguchi K. Abrogation of constitutive STAT3 activity sensitizes human hepatoma cells to TRAIL-mediated apoptosis. J. Hepatol. 2007, 47:546-555.
19. Chen K.F., Tai W.T., Huang J.W., Hsu C.Y., Chen W.L., Cheng A.L., Chen P.J., Shiau C.W. Sorafenib derivatives induce apoptosis through inhibition of STAT3 independent of Raf. Eur. J. Med. Chem. 2011, 46:2845-2851.
20. Chen K.F., Tai W.T., Liu T.H., Huang H.P., Lin Y.C., Shiau C.W., Li P.K., Chen P.J., Cheng A.L. Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3. Clin. Cancer Res. 2010, 16:5189-5199.
21. Han Y., Amin H.M., Franko B., Frantz C., Shi X., Lai R. Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK+ anaplastic large-cell lymphoma. Blood 2006, 108:2796-2803.
22. Witkiewicz A., Raghunath P., Wasik A., Junkins-Hopkins J.M., Jones D., Zhang Q., Odum N., Wasik M.A. Loss of SHP-1 tyrosine phosphatase expression correlates with the advanced stages of cutaneous T-cell lymphoma. Hum. Pathol. 2007, 38:462-467.
23. Pandey M.K., Sung B., Aggarwal B.B. Betulinic acid suppresses STAT3 activation pathway through induction of protein tyrosine phosphatase SHP-1 in human multiple myeloma cells. Int. J. Cancer 2010, 127:282-292.
24. Kunnumakkara A.B., Nair A.S., Sung B., Pandey M.K., Aggarwal B.B. Boswellic acid blocks signal transducers and activators of transcription 3 signaling, proliferation, and survival of multiple myeloma via the protein tyrosine phosphatase SHP-1. Mol. Cancer Res. 2009, 7:118-128.
25. Sandur S.K., Pandey M.K., Sung B., Aggarwal B.B. 5-hydroxy-2-methyl-1,4-naphthoquinone, a vitamin K3 analogue, suppresses STAT3 activation pathway through induction of protein tyrosine phosphatase, SHP-1: potential role in chemosensitization. Mol. Cancer Res. 2010, 8:107-118.
26. Tai W.T., Cheng A.L., Shiau C.W., Huang H.P., Huang J.W., Chen P.J., Chen K.F. Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma. J. Hepatol. 2011, 55:1041-1048.
27. Chen K.F., Yeh P.Y., Hsu C., Hsu C.H., Lu Y.S., Hsieh H.P., Chen P.J., Cheng A.L. Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway. J. Biol. Chem. 2009, 284:11121-11133.
28. Weinstein I.B., Joe A. Oncogene addiction. Cancer Res. 2008, 68:3077-3080.
29. discussion 3080.
30. Villanueva A., Llovet J.M. Targeted therapies for hepatocellular carcinoma. Gastroenterology 2011, 140:1410-1426.
31. Llovet J.M., Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008, 48:1312-1327.
32. Bagnyukova T.V., Tryndyak V.P., Muskhelishvili L., Ross S.A., Beland F.A., Pogribny I.P. Epigenetic downregulation of the suppressor of cytokine signaling 1 (Socs1) gene is associated with the STAT3 activation and development of hepatocellular carcinoma induced by methyl-deficiency in rats. Cell Cycle 2008, 7:3202-3210.
33. Ogata H., Kobayashi T., Chinen T., Takaki H., Sanada T., Minoda Y., Koga K., Takaesu G., Maehara Y., Iida M., Yoshimura A. Deletion of the SOCS3 gene in liver parenchymal cells promotes hepatitis-induced hepatocarcinogenesis. Gastroenterology 2006, 131:179-193.
34. Saxena N.K., Sharma D., Ding X., Lin S., Marra F., Merlin D., Anania F.A. Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. Cancer Res. 2007, 67:2497-2507.
35. Berasain C., Castillo J., Perugorria M.J., Latasa M.U., Prieto J., Avila M.A. Inflammation and liver cancer: new molecular links. Ann. NY Acad. Sci. 2009, 1155:206-221.
36. Yu H., Kortylewski M., Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat. Rev. Immunol. 2007, 7:41-51.
37. Rajendran P., Li F., Manu K.A., Shanmugam M.K., Loo S.Y., Kumar A.P., Sethi G. Gamma-Tocotrienol is a novel inhibitor of constitutive and inducible STAT3 signalling pathway in human hepatocellular carcinoma: potential role as an antiproliferative, pro-apoptotic and chemosensitizing agent. Brit. J. Pharmacol. 2011, 163:283-298.
38. Rajendran P., Ong T.H., Chen L., Li F., Shanmugam M.K., Vali S., Abbasi T., Kapoor S., Sharma A., Kumar A.P., Hui K.M., Sethi G. Suppression of signal transducer and activator of transcription 3 activation by butein inhibits growth of human hepatocellular carcinoma in vivo. Clin. Cancer Res. 2011, 17:1425-1439.
39. Haftchenary S., Avadisian M., Gunning P.T. Inhibiting aberrant Stat3 function with molecular therapeutics: a progress report. Anticancer Drugs 2011, 22:115-127.
40. Tan S.M., Li F., Rajendran P., Kumar A.P., Hui K.M., Sethi G. Identification of beta-escin as a novel inhibitor of signal transducer and activator of transcription 3/Janus-activated kinase 2 signaling pathway that suppresses proliferation and induces apoptosis in human hepatocellular carcinoma cells. J. Pharmacol. Exp. Ther. 2010, 334:285-293.
41. Fischer E.H., Charbonneau H., Tonks N.K. Protein tyrosine phosphatases: a diverse family of intracellular and transmembrane enzymes. Science 1991, 253:401-406.
42. Esposito F., Ammendola R., Faraonio R., Russo T., Cimino F. Redox control of signal transduction, gene expression and cellular senescence. Neurochem. Res. 2004, 29:617-628.
43. Larsen L., Ropke C. Suppressors of cytokine signalling: SOCS. APMIS 2002, 110:833-844.
44. Wu C., Sun M., Liu L., Zhou G.W. The function of the protein tyrosine phosphatase SHP-1 in cancer. Gene 2003, 306:1-12.
45. Wu C., Guan Q., Wang Y., Zhao Z.J., Zhou G.W. SHP-1 suppresses cancer cell growth by promoting degradation of JAK kinases. J. Cell Biochem. 2003, 90:1026-1037.